Azaphilones produced by Penicillium maximae with their cell death-inducing activity on Adriamycin-treated cancer cell

Area of Science:

• Natural Products Chemistry
• Cancer Biology
• Pharmacology

Background:

• Heat shock proteins (Hsps) are implicated in tumor progression and drug resistance.
• Targeting Hsps offers a strategy to enhance cancer chemotherapy.
• Reducing chemotherapeutic agent dosage is crucial for minimizing side effects.

Purpose of the Study:

• To isolate and characterize novel compounds from Penicillium maximae.
• To evaluate the inhibitory effects of isolated compounds on heat shock protein 105 (Hsp105) induction.
• To assess the potential of these compounds in cancer treatment, particularly in combination with Adriamycin (ADR).

Main Methods:

• Isolation and structural elucidation of four new azaphilones (maximazaphilones I-IV) and three known compounds.
• Luciferase assay system utilizing the Hsp105 promoter to evaluate inhibitory effects.
• Assessment of cell death induction in Adriamycin (ADR)-treated HeLa cells.

Main Results:

• Four novel maximazaphilones (1-4) and three known compounds (5-7) were isolated.
• Compounds 2-4, 6, and 7 significantly inhibited Hsp105 promoter activity without cytotoxicity.
• Compounds 1-4, 6, and 7 demonstrated significant cell death induction in ADR-treated HeLa cells, suggesting a synergistic effect.

Conclusions:

• The chemical structures of maximazaphilones I-IV were determined.
• Azaphilones, particularly compounds 2-4, 6, and 7, show promise for cancer therapy by inhibiting Hsp105 expression.
• These findings support the potential use of azaphilones to enhance anticancer drug efficacy and reduce required dosages.